Notice of Results

Diaceutics

29/04/2025 07:00

RNS Number : 4750G

Diaceutics PLC

29 April 2025

 

Diaceutics - Notice of Results & Presentations

New York, Belfast and London, 29 April 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will announce its audited final results for the year ended 31 December 2024 on Tuesday, 13 May 2025.

Analyst Presentation:

A webinar presentation for analysts and investors will be held at 1400 BST (0900 EDT) on Tuesday, 13 May 2025. Those wishing to attend can register their interest using the following link:

 

https://us06web.zoom.us/webinar/register/WN_tH4xZK9CR4iL4FkvLAW0bw

 

Investor Meet Company Presentation:

A webinar presentation for investors will be held via the Investor Meet Company platform at 1530 BST (1030 EDT) on Tuesday, 13 May 2025. The presentation is open to all existing and potential shareholders and registration can be completed via the following link:

 

https://www.investormeetcompany.com/diaceutics-plc/register-investor

 

Enquiries: 

Diaceutics PLC
Ryan Keeling,Chief Executive Officer
Nick Roberts, Chief Financial Officer
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
Canaccord Genuity Limited (Nomad & Broker)
Tel: +44 (0)20 7523 8000
Simon Bridges, Andrew Potts, Harry Rees


 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NORUWRORVSUSUAR